HOME
CAREER NETWORK
NEWS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
BIOPHARM INSIGHT
ABOUT US
NEWSLETTERS FREE Newsletters Archive My eNewsletters NEWS News by Subject News by Date Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Today's Hot Jobs Most Recent Jobs Search Jobs Post Resume Career Resources For Employers COMMUNITY Login Become a Member FAQ PROFILES Company Profiles INDUSTRY EVENTS Clinical RESOURCES Real Estate New Business Opportunities
NEW YORK, July 21 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it is ceasing the clinical development of sumanirole, a compound under investigation for the treatment of Parkinson's disease and Restless Leg Syndrome. The decision is based on results of recent studies that failed to sufficiently distinguish sumanirole from currently available therapies. While the compound may still prove effective in these conditions, it did not meet Pfizer's criteria for continued development. Today's statement is an update to the company's second quarter business performance conference call with financial analysts and media on July 21, 2004.
CONTACT: Paul Fitzhenry, +1-212-733-4637, for Pfizer Inc
Web site: http://www.pfizer.com/
Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visithttp://www.prnewswire.com/comp/688250.html
Company News On-Call: http://www.prnewswire.com/comp/688250.html